SGLT2 inhibitors reduce dementia risk 18% more than GLP-1 drugs in type 2 diabetes patients | Research

The takeaway

Meta-analysis of 9 studies shows SGLT2 inhibitors reduce dementia risk 18% more than incretin mimetics overall (HR 0.82), with larger advantages over DPP-4i (HR 0.67) than GLP-1RA (HR 0.93), particularly benefiting patients over 65.

51% lower vascular dementia risk
SGLT2 inhibitors reduced vascular dementia risk by half compared to incretin therapies in T2D patients, with empagliflozin most consistently protective

What the researchers found

SGLT2i vs incretins overall: HR 0.82. vs DPP-4i: HR 0.67. vs GLP-1RA: HR 0.93. Vascular dementia: HR 0.49. Alzheimer's: HR 0.68. Greater benefit in >65. Empagliflozin most protective.

Why it matters

Dementia affects millions of diabetics. Knowing that drug choice influences dementia risk could shift prescribing patterns—particularly favoring SGLT2 inhibitors for older diabetic patients at cognitive risk.

How the study worked

Systematic review and meta-analysis of PubMed, Embase, Cochrane through Feb 2025. 9 cohort studies. PROSPERO registered.

What this study cannot tell us

Only cohort studies (no RCTs). Potential confounding. Dementia diagnosis methods may vary. SGLT2i vs GLP-1RA comparison barely significant. Cannot determine mechanism.

How to read the evidence

Meta-analysis of 9 cohort studies. Observational evidence—strong signal but needs RCT confirmation.

When this study was published

Published in 2025; literature through February 2025.

The bigger picture

As diabetes and dementia both increase with aging populations, drugs that address both represent enormous public health value. SGLT2 inhibitors' neuroprotective mechanisms (possibly through ketone body production and cerebral blood flow) deserve further investigation.

Questions still open

What mechanism drives SGLT2i neuroprotection?
Should dementia risk influence diabetes drug selection in elderly patients?
Would RCTs confirm the dementia reduction seen in cohort studies?

Common questions

Can diabetes drugs prevent dementia?

This meta-analysis suggests SGLT2 inhibitors (like empagliflozin) may reduce dementia risk more than GLP-1 drugs or DPP-4 inhibitors in type 2 diabetes patients. The reduction was strongest for vascular dementia (51% lower risk) and was greatest in patients over 65.

Should my diabetes medication choice consider brain health?

Based on this evidence, yes—especially for older patients. If you have type 2 diabetes and are concerned about cognitive decline, discussing SGLT2 inhibitors with your doctor could be worthwhile, as they appear to offer neuroprotective benefits beyond blood sugar control.

Read the original research

Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.

Frontiers in endocrinology, 16, 1695075

View on PubMed ↗Publisher’s paper ↗

Citation

Song, Kirim; Choi, Jiwon; Jeong, Dayeon; Shin, Dongyun; Ah, Young-Mi; Lee, Ki Young; Choi, Kyung Hee. (2025). Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.. Frontiers in endocrinology, 16, 1695075. https://doi.org/10.3389/fendo.2025.1695075